文献速递肿瘤 PET/CT核素与放射性配体治疗

基于PET和CT的影像学标准评估放射性药物治疗下胃肠胰神经内分泌肿瘤的疗效

PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy.
PubMed 文献 · J Nucl Med · 2025-05-01

本研究为单中心回顾性研究,纳入178例接受至少2个周期[177Lu]Lu-DOTATATE治疗的G1和G2级胃肠胰神经内分泌肿瘤患者,比较RECIST 1.1、Choi标准与多学科肿瘤委员会评估的分类差异及无进展生存预测价值,并分析分子评分对PFS的预测作用。

要点

  • Choi标准较RECIST 1.1分类出更多进展期和部分缓解患者、更少疾病稳定患者(P<0.01)。
  • RECIST 1.1和Choi标准判定的进展期患者PFS均短于疾病稳定和部分缓解患者(P<0.05)。
  • 基线Krenning评分3分者中位PFS短于4分者(P<0.05)。

核心结论

  • 除RECIST 1.1外,基于PET和CT的影像学标准有潜力评估接受放射性药物治疗的GEP-NETs患者的疗效并预测PFS。
  • 作者认为数据支持使用Choi标准预测PFS及评估疗效一致性。
  • 基线Krenning评分可用于预测2个周期RPT后的治疗反应。

研究设计与样本

  • 单中心回顾性研究,纳入178例G1和G2级GEP-NETs患者,接受至少2个连续周期[177Lu]Lu-DOTATATE治疗。
  • 患者在基线和2个周期RPT后接受生长抑素受体PET/CT检查。
  • PFS定义为从基线至GEP-NET多学科肿瘤委员会(MDT)评估的临床进展或报告死亡的时间。
  • 比较RECIST 1.1、Choi标准与MDT的分类差异及PFS,以MDT定义的PFS为参考评估3年PFS。
  • 分析生长抑素受体标准化报告和数据系统及Krenning分子评分对PFS的预测价值。

主要发现

  • Choi标准较RECIST 1.1分类出更多进展期和部分缓解患者、更少疾病稳定患者(P<0.01)。
  • RECIST 1.1和Choi标准判定的进展期患者PFS均短于疾病稳定和部分缓解患者(P<0.05)。
  • Choi标准与MDT的一致性较RECIST 1.1无显著升高。
  • 基线至随访期间Krenning评分从4分向3分偏移(P<0.01)。
  • 基线Krenning评分3分者中位PFS短于4分者(P<0.05)。

关键数值与推荐

  • Choi标准与RECIST 1.1分类差异有统计学意义(P<0.01)。
  • RECIST 1.1和Choi标准判定的进展期患者PFS均短于疾病稳定和部分缓解患者(P<0.05)。
  • Choi标准与MDT的一致性较RECIST 1.1无显著升高。
  • Krenning评分从基线4分向随访3分偏移(P<0.01)。
  • 基线Krenning评分3分者中位PFS短于4分者(P<0.05)。

临床怎么用

  • 作者认为数据支持使用Choi标准预测PFS及评估疗效一致性。
  • 作者认为基线Krenning评分可用于预测2个周期RPT后的治疗反应。
  • 原文未据此给出其他推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Despite well-documented limitations, current guidelines recommend the use of size-based RECIST 1.1 for response assessment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs) under radiopharmaceutical therapy (RPT). We hypothesize that functional criteria are superior to RECIST 1.1 for response assessment and progression-free survival (PFS) prediction, and molecular scores can be used in prognosticating PFS. Methods: This single-center, retrospective study included 178 patients with GEP-NETs (G1 and G2) who were treated with at least 2 consecutive cycles of RPT with [177Lu]Lu-DOTATATE and who underwent somatostatin receptor PET/CT at baseline and after 2 cycles of RPT (follow-up). PFS was defined as the time between baseline and clinical progression, as reported by a GEP-NET multidisciplinary tumor board (MDT) assessment or reported death. The differences in categorization and PFS between RECIST 1.1, Choi (functional criteria), and the MDT were evaluated, and 3-y PFS with MDT defined PFS as the reference. The predictive values of the different scores in somatostatin receptor standardized reporting and data system and Krenning (molecular scores) for PFS were analyzed. Results: Choi criteria classified a higher number of patients as having progressive disease and partial response and a lower number of patients as having stable disease compared with RECIST 1.1 (P < 0.01). The PFS of patients with progressive disease according to RECIST 1.1 and Choi criteria was shorter than that of patients with stable disease and partial response (P < 0.05). Choi criteria showed a nonsignificantly higher concordance with the MDT than with RECIST 1.1. There was a shift in category from a Krenning score of 4 to a score of 3 between baseline and follow-up (P < 0.01). At baseline, a Krenning score of 3 was associated with a shorter median PFS compared with a score of 4 (P < 0.05). Conclusion: In addition to RECIST 1.1, further PET- and CT-based imaging criteria have the potential to assess response and predict PFS in patients with GEP-NETs undergoing RPT. Our data support the assumption to use Choi criteria for prediction of PFS and agreement in response assessment. At baseline, the Krenning score can be used to predict therapy response after 2 cycles of RPT.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Herr FL, Dascalescu C, Fabritius MP, et al. PET- and CT-Based Imaging Criteria for Response Assessment of Gastroenteropancreatic Neuroendocrine Tumors Under Radiopharmaceutical Therapy. J Nucl Med. 2025. PMID: 40147845. doi:10.2967/jnumed.124.268621

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。